Concurrent use of strontium-89 with external beam radiotherapy for multiple bone metastases: early experience.
Concurrent use of strontium-89 with external beam radiotherapy for multiple bone metastases: early experience.
复制标题
同时使用锶 89 与外照射治疗多发骨转移：早期经验。
DOI：
10.1007/s12149-015-1010-6
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Murayama S.
中科院分区：
文献类型：
--
作者：
Heianna J;Toita T;Endo W;Kasuya G;Ariga T;Hashimoto S;Maemoto H;Terui K;Miura N;Togashi A;Miyauchi T;Murayama S.
本研究的目的是考虑同时使用锶-89（Sr-89）与外照射放射治疗（EBRT）的安全性和有效性的多发性骨转移瘤，包括病变，需要紧急therapy.MethodsA回顾性审查进行了一系列连续的患者谁收到Sr-89多发性骨转移瘤。45例多发性骨转移瘤患者接受了Sr-89注射。由于45例患者中有17例出现溶骨性骨病变，需要紧急EBRT，因此他们接受了Sr-89与EBRT的同时使用（同时组）。其余28例患者，其中没有溶骨性病变需要紧急EBRT，给予Sr-89注射（单一组）。在EBRT期间或EBRT第一天前一天注射Sr-89。EBRT剂量为30戈伊/10次或40戈伊/20次。根据不良事件通用术语标准（V4.0）测量的血液学毒性评价不良事件。为了评估疗效，我们检查疼痛量表和镇痛药物剂量的变化，以及是否存在严重并发症从骨transferas.Results15 17例（88.2%）并发组和17 28例（60.7%）在奇异组报告骨痛缓解。两组之间存在统计学显著差异，并发组中所有患者均可预防骨转移的严重并发症（脊髓压迫和病理性骨折）。两组均未观察到严重血液学毒性（3级或以上）。两组间无统计学差异。没有人需要额外的干预。的不良事件是tolerable.ConclusionsThe我们的研究结果表明，同时使用Sr-89与EBRT的多发性骨转移瘤可以安全地进行，如果它是进行护理，它可能是一种有效的治疗在需要紧急治疗的情况下。
ObjectiveThe aim of the present study was to consider the safety and efficacy of concurrent use of strontium-89 (Sr-89) with external beam radiotherapy (EBRT) for multiple bone metastases, including lesions that require urgent therapy.MethodsA retrospective review was performed of a consecutive series of patients who received Sr-89 for multiple bone metastases. Forty-five patients with multiple bone metastases received Sr-89 injection. Since 17 of the 45 patients had osteolytic bone lesions requiring emergent EBRT, they underwent concurrent use of Sr-89 with EBRT (concurrent group). The remaining 28 patients, none of whom had osteolytic lesions requiring urgent EBRT, were given Sr-89 injection only (singularity group). The injection of Sr-89 was to be given during EBRT, or on the day before the first day of EBRT. The dose of EBRT was 30 Gy in 10 fractions or 40 Gy in 20 fractions. Adverse events were evaluated according to hematological toxicity as measured by the Common Terminology Criteria for Adverse Events (V4.0). To assess efficacy, we checked changes in the pain scale and analgesic drug dosages, and the presence or absence of serious complications from bone metastases.ResultsFifteen of 17 patients (88.2 %) in the concurrent group and 17 of 28 patients (60.7 %) in the singularity group reported bone pain relief. A statistically significant difference was found between the two groups, and severe complications (spinal cord compression and pathological fracture) from bone metastases could be prevented in all patients in the concurrent group. Severe hematological toxicity (grade 3 or higher) was not observed in the two groups. There was no statistical difference between the two groups. No one required additional intervention. The adverse events were tolerable.ConclusionsThe results of our study suggest that concurrent use of Sr-89 with EBRT for multiple bone metastases can be performed safely if it is carried out with care, and that it may be an effective therapy in cases requiring emergency treatment.